Completed
Prospective Ascertainment for Late Effects Among Survivors of Cancer, Tumor, or a Related Illness
What is being collected
Genetic Data
+ genetic Data
+ other Data
Collected from today forward - ProspectiveGeneticOtherDNA Samples
Who is being recruted
+5 Eligibility Criteria
How is the trial designed
Family-Based
Studying health outcomes within families in order to identify genetic or familial contributions to disease.Observational
Study Start: August 2012
Summary
Principal SponsorMemorial Sloan Kettering Cancer Center
Last updated: March 7, 2025
Sourced from a government-validated database.Claim as a partner
Study start date: August 1, 2012
Actual date on which the first participant was enrolled.The purpose of this study is to establish a registry of survivors of cancer, tumor, or a related illness.
Principal SponsorMemorial Sloan Kettering Cancer Center
Last updated: March 7, 2025
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
1068 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Family-Based
These studies involve members of the same family to explore how genetics and shared environments may contribute to a disease. They help researchers pinpoint inherited risk factors.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Criteria
Any sex
Biological sex of participants that are eligible to enroll.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Criteria
3 inclusion criteria required to participate
A personal history of cancer tumor, or a related illness
English speaking
Followed in the the Adult Long Term Follow Up Program, Pediatric Long Term Follow Up Program, or Lymphoma Service at MSKCC
2 exclusion criteria prevent from participating
Evidence of active progression of disease or recurrence
Neurocognitive deficits that impair ability to give informed consent
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Study Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Memorial Sloan Kettering Cancer Center
New York, United StatesOpen Memorial Sloan Kettering Cancer Center in Google MapsCompletedOne Study Center